Stock Analysis
- China
- /
- Medical Equipment
- /
- SHSE:688617
Three High-Growth Stocks With Insider Ownership Exceeding 14%
Reviewed by Simply Wall St
As global markets continue to navigate through fluctuations, with recent data indicating mixed economic signals across major economies, investors remain keenly observant of potential opportunities. In this context, stocks with high insider ownership can be particularly compelling, as significant insider stakes often reflect a leadership's confidence in the company's future growth and alignment with shareholder interests.
Top 10 Growth Companies With High Insider Ownership
Name | Insider Ownership | Earnings Growth |
Gaming Innovation Group (OB:GIG) | 20.2% | 36.2% |
KebNi (OM:KEBNI B) | 37.8% | 90.4% |
HANA Micron (KOSDAQ:A067310) | 20% | 93.4% |
Credo Technology Group Holding (NasdaqGS:CRDO) | 14.9% | 84.1% |
Calliditas Therapeutics (OM:CALTX) | 11.6% | 52.9% |
EHang Holdings (NasdaqGM:EH) | 32.8% | 101.9% |
Seojin SystemLtd (KOSDAQ:A178320) | 26.4% | 48.1% |
Vow (OB:VOW) | 31.8% | 97.6% |
Adocia (ENXTPA:ADOC) | 12.1% | 104.5% |
OSE Immunotherapeutics (ENXTPA:OSE) | 25.6% | 79.3% |
Let's review some notable picks from our screened stocks.
APT Medical (SHSE:688617)
Simply Wall St Growth Rating: ★★★★★★
Overview: APT Medical Inc., based in China, specializes in the research, development, production, and sale of electrophysiology and interventional medical devices with a market capitalization of approximately CN¥29.79 billion.
Operations: The company generates its revenue primarily from the sale of medical products, totaling CN¥1.76 billion.
Insider Ownership: 21.9%
APT Medical Inc. has demonstrated strong growth, with earnings increasing by 45.1% over the past year and expected to grow at 27.44% annually. Revenue forecasts are similarly robust, anticipated to rise by 27.2% per year, outpacing the CN market's average. The company maintains a high level of non-cash earnings and is projected to achieve a significant Return on Equity of 29.1% in three years. Recent strategic moves include the approval of new board members from Shenzhen Mindray Technology, enhancing governance structures following their acquisition of a substantial stake in APT Medical for CNY6.2 billion, completed on April 15, 2024.
- Navigate through the intricacies of APT Medical with our comprehensive analyst estimates report here.
- According our valuation report, there's an indication that APT Medical's share price might be on the expensive side.
King Slide Works (TWSE:2059)
Simply Wall St Growth Rating: ★★★★☆☆
Overview: King Slide Works Co., Ltd. focuses on the research, development, design, and sale of rail kits for servers and network communication equipment in Taiwan, with a market capitalization of approximately NT$114.36 billion.
Operations: The company generates revenue primarily through Chuan Yi Company at NT$5.02 billion and Chuanhu Company at NT$1.82 billion, focusing on the design and sale of rail kits for servers and network communication equipment.
Insider Ownership: 17.5%
King Slide Works Co., Ltd. reported a substantial increase in first-quarter earnings and sales, with net income and sales rising significantly from the previous year. The company's revenue is expected to grow at 22.7% annually, surpassing the Taiwan market average of 11.7%. Despite this, its earnings growth forecast of 14.6% lags behind the market expectation of 18%. Additionally, King Slide has a highly volatile share price but is still trading below analyst price targets, suggesting potential upside according to consensus estimates.
- Unlock comprehensive insights into our analysis of King Slide Works stock in this growth report.
- The valuation report we've compiled suggests that King Slide Works' current price could be inflated.
Chicony Power Technology (TWSE:6412)
Simply Wall St Growth Rating: ★★★★☆☆
Overview: Chicony Power Technology Co., Ltd., based in Taiwan, specializes in manufacturing and selling switching power supplies and LED lighting products, with a market capitalization of approximately NT$54.70 billion.
Operations: The company generates its revenue primarily from domestic sales amounting to NT$34.75 billion, followed by significant contributions from Asia at NT$31.59 billion and a smaller portion from America at NT$0.97 billion.
Insider Ownership: 14.1%
Chicony Power Technology has demonstrated robust financial health with a year-over-year increase in Q1 earnings and sales, reporting TWD 680.86 million in net income. The company's revenue is forecasted to grow at 17.7% annually, outpacing the Taiwanese market's 11.7%. Despite a high insider ownership structure suggesting stable governance, recent executive turnovers could raise concerns about leadership stability. The stock is currently trading at a significant discount to its estimated fair value, potentially offering good value relative to industry peers.
- Click here and access our complete growth analysis report to understand the dynamics of Chicony Power Technology.
- Insights from our recent valuation report point to the potential undervaluation of Chicony Power Technology shares in the market.
Where To Now?
- Click this link to deep-dive into the 1454 companies within our Fast Growing Companies With High Insider Ownership screener.
- Are any of these part of your asset mix? Tap into the analytical power of Simply Wall St's portfolio to get a 360-degree view on how they're shaping up.
- Discover a world of investment opportunities with Simply Wall St's free app and access unparalleled stock analysis across all markets.
Ready For A Different Approach?
- Explore high-performing small cap companies that haven't yet garnered significant analyst attention.
- Diversify your portfolio with solid dividend payers offering reliable income streams to weather potential market turbulence.
- Find companies with promising cash flow potential yet trading below their fair value.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.The analysis only considers stock directly held by insiders. It does not include indirectly owned stock through other vehicles such as corporate and/or trust entities. All forecast revenue and earnings growth rates quoted are in terms of annualised (per annum) growth rates over 1-3 years.
New: Manage All Your Stock Portfolios in One Place
We've created the ultimate portfolio companion for stock investors, and it's free.
• Connect an unlimited number of Portfolios and see your total in one currency
• Be alerted to new Warning Signs or Risks via email or mobile
• Track the Fair Value of your stocks
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com
About SHSE:688617
APT Medical
Engages in the research, development, manufacturing, and supply of electrophysiology and vascular interventional medical devices in China.